Oct 7 (Reuters) - Glaukos said on Wednesday patients treated with its late-stage eye disease therapy maintained improvements ...
Glaukos Corporation (NYSE:GKOS) reported three-year trial results for its non-invasive keratoconus treatment while ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
Please provide your email address to receive an email when new articles are posted on . Classic textbooks teach that the incidence of keratoconus is one per 2,000. That would equate to about 170,000 ...
Arun C. Gulani, MD, introduces a keratoconus classification based on what prevents vision: visual, structural, or salvage.
Three-year data demonstrate sustained improvements in corneal shape, meaningful visual acuity gains, and a favorable ...
Keratoconus is an eye condition that affects the cornea, the transparent outer layer of the eye. Instead of maintaining its usual dome shape, the cornea begins to thin and bulge outward, forming a ...
Please provide your email address to receive an email when new articles are posted on . Patients who underwent cross-linking were younger and white and had commercial insurance. Patients treated with ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
On Monday, Glaukos Corporation (NYSE:GKOS) received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for ...
NBA star Stephen Curry says he had grown accustomed to blurry vision before being diagnosed with keratoconus. Here are the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results